Literature DB >> 16926801

Institute for Quality in Laboratory Medicine series--controversies in laboratory medicine: insights into B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide measurements.

Robert H Christenson1, W H Wilson Tang.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16926801      PMCID： PMC1785227     

Source DB:  PubMed          Journal:  MedGenMed        ISSN： 1531-0132


× No keyword cloud information.
  30 in total

1.  Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.

Authors:  Roberto Latini; Serge Masson; Maylene Wong; Simona Barlera; Elisa Carretta; Lidia Staszewsky; Tarciso Vago; Aldo P Maggioni; Inder S Anand; Lip B Tan; Gianni Tognoni; Jay N Cohn
Journal:  Am J Med       Date:  2006-01       Impact factor: 4.965

2.  Performance characteristics of four automated natriuretic peptide assays.

Authors:  Mindy L Rawlins; William E Owen; William L Roberts
Journal:  Am J Clin Pathol       Date:  2005-03       Impact factor: 2.493

3.  Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure.

Authors:  Adam M Hawkridge; Denise M Heublein; H Robert Bergen; Alessandro Cataliotti; John C Burnett; David C Muddiman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-17       Impact factor: 11.205

4.  Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study.

Authors:  Karen B James; Richard W Troughton; Joseph Feldschuh; Daniel Soltis; Delsa Thomas; Fetnat Fouad-Tarazi
Journal:  Am Heart J       Date:  2005-11       Impact factor: 4.749

5.  B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure.

Authors:  J O O'Neill; C E Bott-Silverman; A T McRae; R W Troughton; K Ng; R C Starling; J B Young
Journal:  Am Heart J       Date:  2005-02       Impact factor: 4.749

6.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study.

Authors:  James L Januzzi; Carlos A Camargo; Saif Anwaruddin; Aaron L Baggish; Annabel A Chen; Daniel G Krauser; Roderick Tung; Renee Cameron; J Tobias Nagurney; Claudia U Chae; Donald M Lloyd-Jones; David F Brown; Stacy Foran-Melanson; Patrick M Sluss; Elizabeth Lee-Lewandrowski; Kent B Lewandrowski
Journal:  Am J Cardiol       Date:  2005-04-15       Impact factor: 2.778

7.  Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease.

Authors:  David A Morrow; James A de Lemos; Michael A Blazing; Marc S Sabatine; Sabina A Murphy; Petr Jarolim; Harvey D White; Keith A A Fox; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2005-12-14       Impact factor: 56.272

8.  Harmonization of the Bayer ADVIA Centaur and Abbott AxSYM automated B-type natriuretic peptide assay in patients on hemodialysis.

Authors:  Mira Barak; Ronit Weinberger; Jerom Marcusohn; Paul Froom
Journal:  Clin Chem Lab Med       Date:  2005       Impact factor: 3.694

9.  The relationship between B-type natriuretic peptide and health status in patients with heart failure.

Authors:  Stacie A Luther; Peter A McCullough; Edward P Havranek; John S Rumsfeld; Philip G Jones; Paul A Heidenreich; Eric D Peterson; Saif S Rathore; Harlan M Krumholz; William S Weintraub; John A Spertus; Frederick A Masoudi
Journal:  J Card Fail       Date:  2005-08       Impact factor: 5.712

10.  Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia.

Authors:  Marc S Sabatine; David A Morrow; James A de Lemos; Torbjorn Omland; Milind Y Desai; Milenko Tanasijevic; Christian Hall; Carolyn H McCabe; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2004-11-16       Impact factor: 24.094
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.